ArriVent BioPharma, Inc.
AVBP
$20.82
-$0.35-1.65%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 218.86M | 282.86M | 298.67M | 317.39M | 150.39M |
Total Receivables | 500.00K | 500.00K | 750.00K | 875.00K | 761.00K |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 407.00K | 1.14M | 1.23M | 1.45M | 368.00K |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 7.21M | 7.90M | 7.87M | 7.76M | 8.45M |
Total Current Assets | 226.98M | 292.40M | 308.51M | 327.48M | 159.97M |
|
|||||
Total Current Assets | 226.98M | 292.40M | 308.51M | 327.48M | 159.97M |
Net Property, Plant & Equipment | 154.00K | 187.00K | 219.00K | 250.00K | 291.00K |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 126.00K | 126.00K | 125.00K | 108.00K | 2.84M |
Total Assets | 274.94M | 292.71M | 308.86M | 327.84M | 163.10M |
|
|||||
Total Accounts Payable | 3.78M | 4.65M | 3.81M | 4.10M | 4.53M |
Total Accrued Expenses | 13.33M | 10.36M | 8.13M | 5.73M | 6.95M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 162.00K | 157.00K | 152.00K | 147.00K | 140.00K |
Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
Total Other Current Liabilities | -- | -- | -- | -- | -- |
Total Current Liabilities | 17.27M | 15.16M | 12.10M | 9.98M | 11.62M |
|
|||||
Total Current Liabilities | 17.27M | 15.16M | 12.10M | 9.98M | 11.62M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | 14.00K | 56.00K | 98.00K | 138.00K | 177.00K |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -- | -- | -- | -- |
Total Liabilities | 17.29M | 15.22M | 12.20M | 10.12M | 11.80M |
|
|||||
Common Stock & APIC | 496.20M | 495.19M | 493.80M | 492.99M | 4.65M |
Retained Earnings | -238.33M | -217.70M | -197.14M | -175.26M | -157.85M |
Treasury Stock & Other | -211.00K | -- | -- | -- | -- |
Total Common Equity | 257.65M | 277.49M | 296.66M | 317.72M | -153.19M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | 304.49M |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | 304.49M |
|
|||||
Total Common Equity | 257.65M | 277.49M | 296.66M | 317.72M | -153.19M |
Total Preferred Equity | -- | -- | -- | -- | 304.49M |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 257.65M | 277.49M | 296.66M | 317.72M | 151.30M |
|